Communiqués Clene Inc.

Actions

CLNN

US1856342019

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/07/2026			Varia. 5j.	Varia. 1 janv.
5,920 ^USD	+4,04%		-5,58%	+0,85%

22/06	Les plus fortes baisses de l'avant-bourse	MT
14/05	Clene Inc conclut un deuxième avenant à ses billets convertibles de premier rang garantis - dépôt SEC	RE

Communiqués

14/05	Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights	AQ
05/05	Clene Announces $7 Million Underwritten Offering of Common Stock	AQ
05/05	Clene to Present at Upcoming May Conferences	AQ
04/05	After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS	AQ
10/04	Clene : 2025 Annual Report to Stockholders	PU
10/04	Clene : 2025 Proxy Statement	PU
10/04	Clene : 2025 Proxy Card	PU
12/03	Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights	AQ
24/02	Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts	AQ
19/02	Clene to Present at the Emerging Growth Conference	AQ
16/01	Clene to Present at the Emerging Growth Conference	AQ
12/01	Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting	AQ
09/01	Clene Announces Registered Direct Offering of Over $28 Million	AQ
09/12	Clene to Present at the Emerging Growth Conference	AQ
03/12	Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®	AQ
02/12	Clene to Provide CNM-Au8® ALS Program Update	AQ
20/11	Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference	AQ
13/11	Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights	AQ
20/10/25	Clene to Present at the Emerging Growth Conference	AQ
15/10/25	Clene to Participate in a Panel Discussion at the Maxim Growth Summit	AQ
25/09/25	Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients	AQ
04/09/25	Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease	AQ
02/09/25	Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference	AQ
14/08/25	Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights	AQ
13/08/25	Clene to Present at the Emerging Growth Conference	AQ